www.immunogen.com
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that develops
targeted cancer therapeutics using its proprietary ADC technology.
ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a
Phase 3 trial for FRa-positive platinum-resistant ovarian cancer, and is
in Phase 1b/2 testing in combination regimens for earlier-stage disease.
ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®,
in other clinical-stage ImmunoGen product candidates, and in programs in
development by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly,
Novartis, Sanofi and Takeda. More information about the Company can be
found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of
the Roche Group.
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including risks related to preclinical and clinical studies, their
timings and results. A review of these risks can be found in ImmunoGen's
Transition Report on Form 10-K for the fiscal year ended December 31,
2016 and other reports filed with the Securities and Exchange Commission.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005083/en/
[ Back To TMCnet.com's Homepage ]